BI 1387446 / Boehringer Ingelheim - LARVOL DELTA

A Study to Find the Best Dose of BI 1387446 Alone or in Combination With Ezabenlimab (BI 754091) in Patients With Different Types of Advanced or Metastatic Cancer (Solid Tumors) (clinicaltrials.gov) - P1 | N=39 | Completed | Sponsor: Boehringer Ingelheim | Active, not recruiting ➔ Completed

Trial completion • Oncology • Solid Tumor

Phase I Trial Evaluating The Sting Agonist BI 1387446 Alone and in Combination with Ezabenlimab in Solid Tumors (JSMO 2024) - No abstract available

Combination therapy • P1 data • Oncology • Solid Tumor

Phase I, first-in-human trial evaluating the STING agonist BI 1387446 alone and in combination with ezabenlimab in solid tumors (ESMO 2023) - P1 | "Table (334/600). Table: 1030P"

Combination therapy • P1 data • Oncology • Solid Tumor

[VIRTUAL] Phase I, first-in-human trial evaluating BI 1387446 (stimulator of interferon genes [STING] agonist) alone and combined with BI 754091 (anti-programmed cell death [PD]-1) in solid tumors (SITC 2020) - P1 | "The trial is currently open for recruitment. Results N/A Conclusions N/A"

P1 data • Oncology • Solid Tumor • STING

A Study to Find the Best Dose of BI 1387446 Alone or in Combination With Ezabenlimab (BI 754091) in Patients With Different Types of Advanced or Metastatic Cancer (Solid Tumors) (clinicaltrials.gov) - P1 | N=39 | Active, not recruiting | Sponsor: Boehringer Ingelheim | Trial completion date: Jun 2024 ➔ Mar 2024

Combination therapy • Metastases • Trial completion date • Oncology • Solid Tumor

A Study to Find the Best Dose of BI 1387446 Alone or in Combination With Ezabenlimab (BI 754091) in Patients With Different Types of Advanced or Metastatic Cancer (Solid Tumors) (clinicaltrials.gov) - P1 | N=39 | Active, not recruiting | Sponsor: Boehringer Ingelheim | N=120 ➔ 39

Combination therapy • Enrollment change • Metastases • Oncology • Solid Tumor

A Study to Find the Best Dose of BI 1387446 Alone or in Combination With Ezabenlimab (BI 754091) in Patients With Different Types of Advanced or Metastatic Cancer (Solid Tumors) (clinicaltrials.gov) - P1 | N=120 | Active, not recruiting | Sponsor: Boehringer Ingelheim | Recruiting ➔ Active, not recruiting

Combination therapy • Enrollment closed • Oncology • Solid Tumor

A Study to Find the Best Dose of BI 1387446 Alone or in Combination With Ezabenlimab (BI 754091) in Patients With Different Types of Advanced or Metastatic Cancer (Solid Tumors) (clinicaltrials.gov) - P1 | N=120 | Recruiting | Sponsor: Boehringer Ingelheim | Trial completion date: Sep 2024 ➔ Jun 2024

Combination therapy • Trial completion date • Oncology • Solid Tumor

A Study to Find the Best Dose of BI 1387446 Alone or in Combination With Ezabenlimab (BI 754091) in Patients With Different Types of Advanced or Metastatic Cancer (Solid Tumors) (clinicaltrials.gov) - P1 | N=120 | Recruiting | Sponsor: Boehringer Ingelheim | Trial completion date: Dec 2025 ➔ Sep 2024

Combination therapy • Trial completion date • Oncology • Solid Tumor

A Study to Find the Best Dose of BI 1387446 Alone or in Combination With Ezabenlimab (BI 754091) in Patients With Different Types of Advanced or Metastatic Cancer (Solid Tumors) (clinicaltrials.gov) - P1 | N=122 | Recruiting | Sponsor: Boehringer Ingelheim | Trial completion date: Jan 2025 ➔ Dec 2025 | Trial primary completion date: Jun 2024 ➔ Feb 2023

Combination therapy • Trial completion date • Trial primary completion date • Oncology • Solid Tumor

[VIRTUAL] Phase I, first-in-human trial evaluating BI 1387446 (stimulator of interferon genes [STING] agonist) alone and combined with BI 754091 (anti-programmed cell death [PD]-1) in solid tumors (SITC 2020) - P1 | "The trial is currently open for recruitment. Results N/A Conclusions N/A"

P1 data • Oncology • Solid Tumor • STING

[VIRTUAL] Phase I, first-in-human trial evaluating BI 1387446 (STING agonist) alone and in combination with ezabenlimab (BI 754091; anti-PD-1) in solid tumors (AACR 2021) - P1 | "Secondary endpoints are objective response rate (based on RECIST 1.1 criteria) and best change from baseline in size of target and injected (and uninjected) lesions. Plasma, blood, and tumor tissue will be collected at baseline and on-therapy for pharmacodynamic analyses.The trial is actively recruiting, and eight patients have been treated as of December 2020."

Combination therapy • P1 data • Oncology • Solid Tumor • STING

A Study to Find the Best Dose of BI 1387446 Alone or in Combination With Ezabenlimab (BI 754091) in Patients With Different Types of Advanced or Metastatic Cancer (Solid Tumors) (clinicaltrials.gov) - P1; N=122; Recruiting; Sponsor: Boehringer Ingelheim; N=266 ➔ 122

Clinical • Combination therapy • Enrollment change • Oncology • Solid Tumor

A Study to Find the Best Dose of BI 1387446 Alone or in Combination With BI 754091 in Patients With Different Types of Advanced or Metastatic Cancer (Solid Tumors) (clinicaltrials.gov) - P1; N=266; Recruiting; Sponsor: Boehringer Ingelheim; Trial completion date: Dec 2023 ➔ Mar 2025; Trial primary completion date: Feb 2023 ➔ Jul 2024

Clinical • Combination therapy • Trial completion date • Trial primary completion date • Oncology • Solid Tumor

A Study to Find the Best Dose of BI 1387446 Alone or in Combination With BI 754091 in Patients With Different Types of Advanced or Metastatic Cancer (Solid Tumors) (clinicaltrials.gov) - P1; N=266; Recruiting; Sponsor: Boehringer Ingelheim; Suspended ➔ Recruiting

Clinical • Combination therapy • Enrollment open • Oncology • Solid Tumor

A Study to Find the Best Dose of BI 1387446 Alone or in Combination With BI 754091 in Patients With Different Types of Advanced or Metastatic Cancer (Solid Tumors) (clinicaltrials.gov) - P1; N=266; Suspended; Sponsor: Boehringer Ingelheim; Not yet recruiting ➔ Suspended

Clinical • Combination therapy • Trial suspension • Oncology • Solid Tumor

A Study to Find the Best Dose of BI 1387446 Alone or in Combination With BI 754091 in Patients With Different Types of Advanced or Metastatic Cancer (Solid Tumors) (clinicaltrials.gov) - P1; N=266; Not yet recruiting; Sponsor: Boehringer Ingelheim; Trial primary completion date: Aug 2023 ➔ Feb 2023

Clinical • Combination therapy • Trial primary completion date